VIJAYAKUMAR A R

Dr. VIJAYAKUMAR A R

PHARMACOLOGY, Bharath University, Chennai, India
orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 June 2025 in International Journal of Basic & Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
VSVijayakumar S.
Vijayakumar S.
PSParimalakrishnan S.
Parimalakrishnan S.
PCPrem Anand D. C.
Prem Anand D. C.
MSMonisha S.
Monisha S.
VIVishnuvarthini
Vishnuvarthini
VIJAYAKUMAR A RVIJAYAKUMAR A R
VIJAYAKUMAR A R
Osteoporosis is a global health concern, marked by reduced bone density and increased fracture of risk, which unfavorably impacts quality of life and results substantial burdens on healthcare systems. This condition often progresses asymptomatically, with fractures, functional decline, and rise in mortality emerging in advanced stages. However, projections indicate that by 2050, over 50% of global osteoporotic fractures will occur in Asia, highlighting the urgency for targeted interventions. Early detection is very crucial for mitigating osteoporosis-associated morbidity. Screening programs enable timely identification of at-risk individuals, may facilitating interventions such as pharmacological therapy and lifestyle modifications that significantly lower the fracture incidence. Furthermore, community-based awareness campaigns may be playing a critical role in promoting bone health by encouraging sufficient intake of calcium and vitamin D supplement, in-addition regular to do physical activity. A life-course approach to bone health is essential. In postmenopausal women, pharmacological and non-pharmacological treatments, lifestyle strategies are imperative for decline bone loss and preventing bone fractures. To achieve optimal bone mineral density (BMD) and postpone the onset of disease, premenopausal women must receive early preventive measure care and proper education. However, substantial rise in the prevalence of osteoporosis worldwide suggests to improve awareness among the public, expand access to healthcare, and create all-encompassing prevention and management plans. In order to lessen the significant societal and economic effects of this silent epidemic, multidisciplinary collaboration and continuing public health initiatives are essential.


1 January 2010 in Methods and Findings in Experimental and Clinical Pharmacology
Verified
Journal Article
Closed access
TVT. Velpandian
T. Velpandian
JNJayabalan Nirmal
Jayabalan Nirmal
PGP. Gupta
P. Gupta
VIJAYAKUMAR A RVIJAYAKUMAR A R
VIJAYAKUMAR A R
SGS. Ghose
S. Ghose
The present study evaluated the protective action of calcium dobesilate (CDO) in various experimental models of cataract. CDO was studied in hydrocortisone-induced cataract in developing chick embryos and selenite-induced cataract in pups. CDO anti-cataract activity was also evaluated after oral and topical application as eye drops in galactose (30%) fed rats. This study was further extended to evaluate the intraocular penetration of a single dose of 1% CDO (50 microL) in rabbits. CDO exhibited significant protection against cataract in experimental models and considerable penetration after single topical application. Anti-cataract activity may be due to its antioxidant as well as aldose reductase inhibitor properties. Further studies are in progress to evaluate its clinical efficacy in diabetic cataract.


25 May 2021 in International Journal of Basic & Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
VIJAYAKUMAR A RVIJAYAKUMAR A R
VIJAYAKUMAR A R
PEPrabu Daniel Epison
Prabu Daniel Epison
KAKabeera Begum A.
Kabeera Begum A.
APAbirami V. P.
Abirami V. P.
AHAjmal Hussain
Ajmal Hussain
AAAnsar Ali Abdunnasir
Ansar Ali Abdunnasir
Several systemic drugs have reported ocular and visual side effects that affect patient management. It is imperative to be familiar with the associated side effects which can be mild or transient and may seriously threaten vision. This article deals briefly with the mechanisms and reasons that account for the impact that systemically administered central nervous system (CNS) drugs can exert on the visual or ocular system. The eye care practitioner can be instrumental in detecting and reporting ocular side effects, advising patients and collaborating with other members of the patient’s healthcare team. One of the difficulties include becoming familiar with the countless systemic medications prescribed to patients. Another is being able to correlate a particular side effect with a suspected drug. Several of the ocular adverse effects such as glaucoma, cataract, blurred vision, color vision, optic neuritis, maculopathy, dry eye, etc., are vision threatening and often patients fail to recognize or describe the symptoms appropriately. Therefore, physicians and paramedical members like staff nurses, clinical pharmacists and other members must make adequate observations while recommending these drugs to patients.

25 June 2020 in SN Comprehensive Clinical Medicine
Verified
Journal Article
Closed access
PDF file
SVShoban Babu Varthya
Shoban Babu Varthya
PTPugazhenthan Thangaraju
Pugazhenthan Thangaraju
SVSajitha Venkatesan
Sajitha Venkatesan
VIJAYAKUMAR A RVIJAYAKUMAR A R
VIJAYAKUMAR A R
ETEswaran Thangaraju
Eswaran Thangaraju